Trial Profile
Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary)
- Indications Abscess; Cellulitis; Erysipelas
- Focus Adverse reactions
- Sponsors Trius Therapeutics
- 05 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2012 New trial record